novo nordisk chronic kidney disease

Novo Nordisk’s Ozempic Gets FDA Approval

FDA approves Novo Nordisk's Ozempic to treat chronic kidney disease in those with diabetes, expanding its use

Expanded Ozempic approval in the U.S. could transform how doctors treat patients with chronic kidney disease, which involves a gradual loss of kidney function.

Reuters on MSN · 1d

US FDA approves Novo Nordisk's Ozempic to cut risk of diabetic kidney disease progression

The U.S. FDA has approved Novo Nordisk's Ozempic for reducing the risk of kidney failure and disease progression, as well as death due to heart problems in diabetes patients with chronic kidney disease (CKD),

The Wall Street Journal on MSN · 2d

Novo Nordisk’s Ozempic Gets FDA Approval as Kidney-Disease Treatment

Ozempic, or semaglutide, can now be used to reduce the risk of worsening kidney disease or kidney failure in adults with type 2 diabetes and chronic kidney disease, Novo Nordisk said.

2don MSN

Novo Nordisk's Ozempic gets FDA approval for kidney disease

Novo Nordisk (NVO) said its popular diabetes drug Ozempic, or semaglutide, has been approved for the treatment of patients ...

16hon MSN

Novo Nordisk's SWOT analysis: stock outlook amid GLP-1 market growth

A/S, a global healthcare company specializing in diabetes care and other chronic conditions, has been at the forefront of the rapidly expanding GLP-1 market. With a market capitalization of $376.79 ...

Novo Nordisk's new CagriSema obesity drug trial to begin on Feb. 10, clinicaltrials.gov entry shows

Novo Nordisk will begin a new late-stage trial of its experimental next-generation obesity drug CagriSema on Feb. 10, according to a entry.

22h

Are weight-loss drugs like gym memberships? The answer is worth billions

An analyst thinks he has cracked the code on why highflying Eli Lilly missed two quarters of Wall Street projections.

Results that may be inaccessible to you are currently showing.

Hide inaccessible results